Outpatient Internal Medicine DCACP Annual Scientific Meeting November 2014
|
|
- Kristina Burke
- 8 years ago
- Views:
Transcription
1 Outpatient Internal Medicine 2014 DCACP Annual Scientific Meeting November 2014
2 Two papers appeared in the June 26, 2014 edition of the NEJM studying the question of how long to monitor heart rhythm after CVAs and TIAs looking for episodes of Atrial Fibrillation Why were these studies performed?
3 Rationale for the studies Current guidelines recommend at least 24 hrs of rhythm monitoring after an ischemic stroke to rule out AFib. However, the most effective duration and type of monitoring have not been established and the cause of ischemic stroke remains uncertain despite a complete diagnostic evaluation in 20-40% of cases.
4 Atrial Fibrillation in Patients with Cryptogenic Stroke NEJM 370;26: (June 26, 2014) Study included 572 patients age 55 yrs or older without known Afib with cryptogenic TIA or ischemic CVA within prior 6 months Patients were randomly assigned to either i) a conventional 24 hour monitor OR ii) a 30 day event-triggered recorder PRIMARY OUTCOME was a newly detected A fib episode of at least 30 seconds in duration within 90 days of randomization
5 Incremental Yield of Prolonged ECG Monitoring for the Detection of Atrial Fibrillation in Patients with Cryptogenic Stroke or TIA. Gladstone DJ et al. N Engl J Med 2014;370:
6 Cryptogenic Stroke and Underlying Atrial Fibrillation NEJM 370;26: Randomized controlled study of 441 patients at least 40 yrs old with cryptogenic TIA/CVA with no evidence of Afib during at least 24 hrs monitoring Patient randomization within 90 days p TIA/CVA to either (i) insertable cardiac monitor (ICM) OR (ii) no ICM End Points: First episode of Afib lasting >30 seconds in 6 months and in12 months
7 Time to First Detection of Atrial Fibrillation. Sanna T et al. N Engl J Med 2014;370:
8 Limitations of study 1. It was unclear whether newly discovered A Fib was causally related to the index stroke. 2. Clinical significance of brief episodes of Atrial Fib detected with an ICM is unknown. 3. Not all episodes of A Fib could be accounted for because the devices had limited memory capacity
9 My father hopes you are enjoying this presentation as much as I enjoyed my pizza
10 Osteoporosis and its treatment Though Prolia is becoming increasingly popular as a treatment for osteoporosis, bisphosphonates (BSPNs )have been the basic pharmacologic treatment for many years now. However, there many questions have been raised in recent years about risks of BSPNs, how long to continue treatment, and what is the value of drug holidays (and how long should they last?)
11 Risk of Atypical Femoral Fracture during and after Bisphosphonate Use NEJM October 11, 2014 representing an extension of NEJM May 5, 2011 report May 2011 study : Case Control Study involving 1234 Swedish women 55 yrs and older with xrays showing subtrochanteric or shaft fractures between 2005 and October 2014 extension: 2 years more data involving 5342 men and women 55 yrs and older with xrays showing femoral shaft fxs
12 Cohort study CASES were patients with atypical fxs who received Bisphosphonates (BSPHs) CONTROLs were patients who had similar fractures but who had not received BSPNs.
13 Risk of Atypical Femoral Fxs on BSPNs vs Not on BSPNs(5 yr data) Multivariate Adj Odds Ratio Duration of use: <1.0 yrs yrs yrs yrs yrs However, annual absolute risk of atypical fracture was -- After 2 years of BSPNs: 2/10,000 pt years of tx -- After 4 years of BSPN : 11/10,000 pt years of tx
14 How Does Risk Diminish off BSPNs? Time since last use <1 year /10,000 Pt yrs years 3.5 <1/10,000 Pt yrs years 3.2 <1/10,000 Pt yrs
15 Your patients have heard about THE BIG T--
16 The Big T (before)
17 The Big T (after)
18 The BIG T Advertisements promote testosterone replacement for men with decreased energy and low sex drive. There is scientific evidence to suggest that in at least some men with low energy testosterone replacement can boost energy, increase libido, improve bone mineral density, and improve lean body mass and strength.
19 Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke in Men with Low Testosterone Levels JAMA 310(17): (November 2013) Retrospective national cohort study of men with low testosterone levels (<300 ng/dl) who underwent coronary angiography in the VA system between Primary outcome a composite of all-cause mortality and hospitalization for MI or ischemic stroke
20 From: Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels JAMA. 2013;310(17): doi: /jama Figure Legend: Kaplan-Meier Survival Curves With Testosterone Therapy Evaluated as a Time-Varying Covariate Date of download: 11/2/2014 Copyright 2014 American Medical Association. All rights reserved.
21 Association of Testosterone Therapy with Mortality, MI, and CVA (JAMA) Kaplan-Meier estimated cumulative percentages of men with outcome event No Testo vs Testo Years since Angiogram One Yr Two Yr Three Yr No testosterone 10.1% 15.4% 19.9% Testosterone 11.3% 18.5% 25.7%
22 Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men PLOS One. 2014;9:e85805 Data based used: The Truven Health MarketScan Commercial Claims and Encounters Database (employees, dependents and retirees with commercial or Medicare insurance whose employers license healthcare data to Truven Health Analytic (Truven). The MarketScan data contributors include Fortune 500 employers (60%) and health plans covering other companies and unions (40%)
23 PLOS ONE An open access peer-reviewed scientific journal published by the Public Library of Science since Concept was a free-access biomedical journal challenging academia s obsession with journal status and impact factors Financed by charging authors a publication fee According to Wikipedia, the journal published 31,500 papers in 2013 (apparently making it the largest journal in the world by volume)
24 Key comparisons in this study Outcome event was a dx of Acute MI (ICD9 Code of 410) occurring within 90 days after men filled a first prescription for testosterone (n=55,593). The incidence of these outcome events were compared to the incidence of Acute MI occurring one year prior to the first prescription for testosterone. (Data not available on how much of the prescribed medication was consumed).
25 Table 1. Rates of myocardial infarction per 1,000 persons per year (PY) in men under age 65 years and those age 65 years and older, in pre- and post-prescription intervals for an initial prescription for testosterone therapy rate ratios (RR) and 95% confidence intervals (CI). Finkle WD, Greenland S, Ridgeway GK, Adams JL, et al. (2014) Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE 9(1): e doi: /journal.pone
26 Testosterone and Mortality Clin Endocrinol 2014;81(4): Epidemiologic studies have found that men with low or low normal endogenous testosterone are at an increased risk of mortality than those with higher levels. Similarly, multiple epidemiologic studies have shown a link between low testosterone and cardiovascular disease. Of the studies linking mortality with low testosterone, increased mortality was mostly attributable to cardiovascular mortality.
27 And, the other major point of the Clin Endocinology article The studies of testosterone replacement are flawed in terms of lacking potentially important data, such as to whether replacement has been done to a normal healthy range or not (e.g., there is a recent French study of 3650 men aged 65 and older where a J-shaped association was found between total testosterone levels and ischemic arterial disease. The studies of testosterone replacement have significant methodologic limitations
28 Some limitations of JAMA study Patients were included who were started on testosterone therapy at variable intervals after the initial angiogram (median of 531 days following angiography) Patients were included if they filled a first prescription for testosterone following angiography. Once initiated, a patient was assumed to have continued treatment until an outcome event occurred or the end of follow up
29 Limitations in PLOS study No data on whether or not hypogonadism had been diagnosed or even if testosterone levels were measured No evidence on compliance or monitoring of testosterone levels No data on fatal MIs
30 2014 FDA Testosterone Actions On January 31, 2014, FDA issued a Drug Safety Communication informing the public of its investigation of "the risk of stroke, heart attack, and death" in men taking FDA-approved testosterone products
31 Sept 17 th FDA meeting Panel members at a joint meeting of the Bone Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM) voted 20-1 in favor of changing the labeling of the testosterone replacement therapy. A second vote calling on companies to conduct studies related to cardiovascular risks also yielded a tally in favor of such trials. The majority of those voting advised narrowing the set of indicators to distinguish classic hypogonadism, such as pituitary or testicular diseases, from hypogonadism due to old age.
32 And as might be expected Lawsuits have been filed against the makers of testosterone therapies, alleging patients were harmed by the use of testosterone and that they were not adequately warned about the risks involved with the therapy.
33 These presentation are almost as exciting as a MSL soccer game
34 So what about all those patients who don t enjoy colonoscopy? And what is the role of newer stool tests in screening for colon cancer?
35 Multitarget Stool DNA Testing for Colorectal-Cancer Screening NEJM 2014;370: (April 2014) From June 2011 to November ,776 asymptomatic persons ages at average risk for colorectal cancer who were scheduled to undergo screening colonoscopy were enrolled at 90 sites throughout the US and Canada (enrollment weighted towards persons 65 yrs or older to increase prevalence of cancer) of these participants (78.2%) had results that could be fully evaluated.
36 Enrollment and Outcomes. Imperiale TF et al. N Engl J Med 2014;370:
37 Multitarget Stool DNA (MTSD) Testing for Colorectal-Cancer Screening: Outcomes The primary outcome was the ability of the MTSD test to detect colorectal cancer. The 2o outcome was the performance of the MTSD test for the detection of advanced precancerous lesions including Advanced Adenomas with high-grade dysplasia or with at least 25% villous histologic features or measuring at least 1 cm in greatest dimension Sessile serrated polyps of at least 1 cm in diameter
38 MTSD Testing for Colorectal-Cancer Screening: The Stool Test Itself The MTSD test consisted of assays for aberrantly methylated BMP3 and NDRG4 promoter regions, mutant KRAS, and Beta-actin, as well as an immunochemical assay for human hemoglobin Gold Standard were results from follow up colonoscopy. Results were also compared to those from an immunochemical assay for human hemoglobin (FIT test)
39 Sensitivity and Specificity of the Multitarget Stool DNA Test and the Fecal Immunochemical Test (FIT) for the Most Advanced Findings on Colonoscopy. Imperiale TF et al. N Engl J Med 2014;370:
40 Numbers of Persons Who Would Need to Be Screened with Colonoscopy, Multitarget DNA Test, and FIT to Detect One Colorectal Cancer and One Advanced Precancerous Lesion. Imperiale TF et al. N Engl J Med 2014;370:
41 False Positive results for the MTSD test and FIT test False positive rate of MTSD test 13.4% for non advanced adenomas and no adenomas (16.3% for those 65 and older) and 10.2% for no adenomas at all False positive rate of the FIT test was 5.1% for advanced adenomas and no adenomas and 3.6% for no adenomas at all
42 A Pooled Analysis of Advanced Colorectal Neoplasia Diagnoses After Colonoscopic Polypectomy Gastroenterology 2009;136: Individual data from 8 prospective studies comprising 9167 men and women aged with previously resected colorectal adenomas to quantify their risk of developing subsequent advanced adenoma or cancer, as well as identify factors associated with the development of advanced adenoma or cancer
43 A Pooled Analysis of Advanced Colorectal Neoplasia Diagnoses After Colonoscopic Polypectomy: Results During a median follow up period of 47.2 months, advanced adenoma or neoplasia was diagnosed in 11.8% of the patients. 58 of the patients (o.6%) had invasive colon cancer Risk of advanced adenomas or neoplasm was highest in certain subgroups
44 Gastroenterology , DOI: ( /j.gastro ) Copyright 2009 AGA Institute Terms and Conditions Figure 1
45 Polypectomy May Reduce Risk of Death from Colon Cancer NEJM 2012;366: Feb 23, 2012 Data from the National Polyp Study (NPS) was analyzed. Subjects in this trial were patients referred for colonoscopy between 11/80 and 2/90. Patients were referred for colonoscopy because of positive findings on BaEnema (27%), sigmoidoscopy (15%), Positive occult test (11%), other tests (10%), Symptoms (32%), or family history of colon cancer (5%).
46 Outcomes sought Death rates from colon cancer of the 2602 patients who had adenomas removed during participation in the study after a median of 15.8 years were compared to the estimated number of expected deaths from colorectal cancer in the general population Study participants had colonoscopies offered at 1, 3, and 6 years or at 1 and 6 years.
47 Deaths from Colorectal Cancer in the Adenoma Cohort, as Compared with Incidence-Based Mortality from Colorectal Cancer in the General Population. Zauber AG et al. N Engl J Med 2012;366:
48 Cumulative Mortality from Colorectal Cancer in the General Population, as Compared with the Adenoma and Nonadenoma Cohorts. Zauber AG et al. N Engl J Med 2012;366:
49 Tabular data analysis
50 And, finally, what about the practical aspects of Cologuard Testing Decision Memo for Screening for Colorectal Cancer-Stool DNA Testing (CAG-00440N) the Centers for Medicare and Medicaid Services (CMS) has determined that the evidence is sufficient to cover Cologuard as a colorectal cancer screeing test for asymptomatic, average risk beneficiaries, aged years.
51 CMS Memo: The details CMS will cover the Cologuard test once every three years if: 1. Age yrs old 2. Asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower GI pain, blood in stool, positive guiac fecal occult or fecal immunochemical test, AND 3. At average risk (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease and no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary non polyposis colorectal cancer.)
52 And what about private insurance coverage 1. $50 deposit required for specimen to be processed 2. The Cologuard company will then work to collect payment from the patient s private insurance company 3. Patient is responsible for amount not covered by the insurance company (maximum of $599)
53 Thank you for your attention to my father s presentation
54 Characteristics of the Five Patients with Colorectal Cancer (Malignant Polyp) Detected at Follow-up Colonoscopy. Winawer SJ et al. N Engl J Med 1993;329:
55 Prevention of Colorectal Cancer by Colonoscopic Polypectomy NEJM 1993;329: Data from the National Polyp Study (NPS) was analyzed. Subjects in this trial were patients referred for colonoscopy between 11/80 and 2/90. Patients were referred for colonoscopy because of positive findings on BaEnema (27%), sigmoidoscopy (15%), Positive occult test (11%), other tests (10%), Symptoms (32%), or family history of colon cancer (5%).
A list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke
More informationTestosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS
Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone
More informationFebruary 25, 2014. Dear Dr. Hamburg:
February 25, 2014 Margaret A. Hamburg, M.D. Commissioner Food and Drug Administration Department of Health and Human Services WO 2200 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 Division of
More informationTESTOSTERONE The Future?
TESTOSTERONE The Future? Martin M. Miner MD Co-Director Men s Health Center The Miriam Hospital Clinical Professor of Family Medicine and Urology Warren Alpert School of Medicine of Brown University Providence,
More informationClinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Frequency of visit as recommended by PCP
SCREENING EXAMINATION & COUNSELING UPMC Health Plan Clinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Annually Physical Exam and Counseling 1 Blood Pressure 2 At each visit. At least
More informationEpi procolon The Blood Test for Colorectal Cancer Screening
Epi procolon The Blood Test for Colorectal Cancer Screening Epi procolon is an approved blood test for colorectal cancer screening. The US Preventive Services Task Force, the American Cancer Society and
More informationCOLORECTAL CANCER SCREENING
COLORECTAL CANCER SCREENING By Douglas K. Rex, M.D., FACG & Suthat Liangpunsakul, M.D. Division of Gastroenterology and Hepatology, Department of Medicine Indiana University School of Medicine Indianapolis,
More informationScreening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group
Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection
More informationTestosterone Treatment in Older Men
Testosterone Treatment in Older Men J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships to disclose.
More informationBlood-based SEPT9 Test in Colorectal Cancer Detection
Prof. JIANQIU SHENG, PENG JIN, YING HAN GI UNIT, BEIJING MILITARY GENERAL HOSPITAL Blood-based SEPT9 Test in Colorectal Cancer Detection A Report of Preliminary Study in China Disclosure of Interest: Nothing
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationInequalities in Colon Cancer
Inequalities in Colon Cancer Chyke Doubeni, MD, FRCS, MPH Chair and The Presidential Associate Professor Department of Family Medicine and Community Health Perelman School of Medicine Senior Scholar, Center
More informationAs Reported by the Senate Health, Human Services and Aging Committee. 127th General Assembly Regular Session Sub. S. B. No. 278 2007-2008 A B I L L
As Reported by the Senate Health, Human Services and Aging Committee 127th General Assembly Regular Session Sub. S. B. No. 278 2007-2008 Senator Coughlin Cosponsors: Senators Stivers, Mumper, Spada, Miller,
More informationSummary of Cancer Prevention and Screening Benefits of the Affordable Care Act (ACA) in Kentucky for health professionals
Summary of Cancer Prevention and Screening Benefits of the Affordable Care Act (ACA) in Kentucky for health professionals Talk with patients about ü Potential benefits, harms, and unknowns of cancer ü
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationTestosterone, Growth Hormone and Bioidentical Hormones Prescription Issues
Testosterone, Growth Hormone and Bioidentical Hormones Prescription Issues T. Brooks Vaughan III, MD Department of Endocrinology UAB July 11, 2015 Brooks Vaughan, MD Associate Professor, Medicine, Pediatrics
More informationMalmö Preventive Project. Cardiovascular Endpoints
Malmö Preventive Project Department of Clinical Sciences Malmö University Hospital Lund University Malmö Preventive Project Cardiovascular Endpoints End of follow-up: 31 Dec 2008 * Report: 21 June 2010
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationCancer screening: indications, benefits and myths
Cancer screening: indications, benefits and myths Silvia Deandrea Institute for Health and Consumer Protection Public Health Policy Support Unit Healthcare Quality Team Joint Research Centre The European
More informationMalmö Preventive Project. Cardiovascular Endpoints
Malmö Preventive Project Department of Clinical Sciences Skåne University Hospital, Malmö Lund University Malmö Preventive Project Cardiovascular Endpoints End of follow-up: 30 June 2009 Report: 7 October
More informationThe Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention
The Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention Robert B. Wallace, MD, MSc Departments of Epidemiology and Internal Medicine University of Iowa College of Public Health
More informationRandomized trials versus observational studies
Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James
More informationCancer Screening. Robert L. Robinson, MD, MS. Ambulatory Conference SIU School of Medicine Department of Internal Medicine.
Cancer Screening Robert L. Robinson, MD, MS Ambulatory Conference SIU School of Medicine Department of Internal Medicine March 13, 2003 Why screen for cancer? Early diagnosis often has a favorable prognosis
More informationCardiovascular Endpoints
The Malmö Diet and Cancer Study Department of Clinical Sciences Malmö University Hospital Lund University The Malmö Diet and Cancer Study CV-cohort Cardiovascular Endpoints End of follow-up: 31 Dec * Report:
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationAndrogens and CVD. Brandon Orr- Walker April 2014
Androgens and CVD Brandon Orr- Walker April 2014 Agenda What is normal physiology of Aging? Hypogonadism and disease If some is good is more becer? CVD safety Clinical features of Androgen Deficiency
More informationCancer screening: cost-effectiveness. Endoscopic polypectomy: : CRC mortality. Endoscopic polypectomy: : CRC incidence
Cribado del cáncer (colorrectal): las pruebas de detección precoz salvan vidas Dr. Antoni Castells Servicio de Gastroenterología Hospital Clínic nic,, Barcelona (castells@clinic.cat) Conditions for a population-based
More informationJournal of Men s Health Editorial. Death by Testosterone?
Journal of Men s Health Editorial 2/20/14 Death by Testosterone? Martin Miner MD Co- Director Men s Health Center The Miriam Hospital Clinical Associate Professor of Family Medicine and Urology The Warren
More informationEXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA
EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA A CASE STUDY EXAMINING RISK FACTORS AND COSTS OF UNCONTROLLED HYPERTENSION ISPOR 2013 WORKSHOP
More informationScreening for colorectal cancer (CRC) in asymptomatic patients
GASTROENTEROLOGY 2012;143:844 857 Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer DAVID A. LIEBERMAN,*
More informationPROSTATE CANCER SCREENING PROSTATE CANCER SCREENING
3:45 4:45pm Screening Guidelines for Men's Health SPEAKER Radha Rao, MD Presenter Disclosure Information The following relationships exist related to this presentation: Radha Rao, MD: No financial relationships
More informationEarly Detection of Colorectal Cancer Made Easy with a Blood Test
INFORMATION FOR PHYSICIANS Early Detection of Colorectal Cancer Made Easy with a Blood Test Epi pro Colon 2.0 : 2 nd Generation Septin 9 Test CRC SCREENING SAVES LIVES Colorectal cancer is a major health
More informationCardiovascular Endpoints
The Malmö Diet and Cancer Study Department of Clinical Sciences Skåne University Hospital, Malmö Lund University The Malmö Diet and Cancer Study CV-cohort Cardiovascular Endpoints End of follow-up: 30
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationCMS Denies Medicare Reimbursement Eligibility for Virtual Colonoscopies
CMS Denies Medicare Reimbursement Eligibility for Virtual Colonoscopies By Craig A. Conway, J.D., LL.M. The Centers for Medicare and Medicaid Services (CMS) recently issued a memorandum stating that it
More informationColonoscopy Data Collection Form
Identifier: Sociodemographic Information Type: Zip Code: Gender: Height: (inches) Race: Ethnicity Inpatient Outpatient Male Female Birth Date: Weight: (pounds) American Indian (Native American) or Alaska
More informationThe Forzani MacPhail Colon Cancer Screening Centre Frequently Asked Questions. What is the Forzani MacPhail Colon Cancer Screening Centre?
The Forzani MacPhail Colon Cancer Screening Centre Frequently Asked Questions What is the Forzani MacPhail Colon Cancer Screening Centre? The Forzani and MacPhail Colon Cancer Screening Centre (CCSC) is
More informationNDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION AbbVie, Inc. Attention: Gennadiy
More informationPDL Class: Topical Androgens
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Topical Androgens Month/Year of Review:
More informationSafety & Effectiveness of Drug Therapies for Type 2 Diabetes: Are pharmacoepi studies part of the problem, or part of the solution?
Safety & Effectiveness of Drug Therapies for Type 2 Diabetes: Are pharmacoepi studies part of the problem, or part of the solution? IDEG Training Workshop Melbourne, Australia November 29, 2013 Jeffrey
More informationGuide to Biostatistics
MedPage Tools Guide to Biostatistics Study Designs Here is a compilation of important epidemiologic and common biostatistical terms used in medical research. You can use it as a reference guide when reading
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationNeal Rouzier responds to the JAMA article on Men and Testosterone
Neal Rouzier responds to the JAMA article on Men and Testosterone On the first day the JAMA article was released I received 500 emails from physicians and patients requesting my opinion of the article
More informationData Trends Report. Encuity. Testosterone Replacement Therapy
Encuity Data Trends Report Encuity has cost-effective solutions to suit your business needs through our various syndicated services. Encuity Data Trends Report provides insight on how our collective services
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationQuantifying Life expectancy in people with Type 2 diabetes
School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationPhysician and other health professional services
O n l i n e A p p e n d i x e s 4 Physician and other health professional services 4-A O n l i n e A p p e n d i x Access to physician and other health professional services 4 a1 Access to physician care
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationHEdis Code Quick Reference Guide Disease Management Services
HEdis Code Quick Reference Guide Disease Management Services Respiratory Conditions Appropriate Testing for Children With Pharyngitis (ages 2-18) [Commercial, Medicaid] Appropriate Treatment (no antibiotic)
More informationYour Guide to Medicare s Preventive Services
Your Guide to Medicare s Preventive Services C E N T E R S F O R M E D I C A R E & M E D I C A I D S E R V I C E S This is the official government booklet with important information about: What disease
More informationExact Sciences Corporation October 2, 2014
Exact Sciences Corporation October 2, 2014 (EXAS: NASDAQ--$18.75) John M. Putnam, CFA BUY-- Target Price $34 Exact Sciences Corp. (EXAS-NASDAQ-$18.75-BUY) Tackling a Major Killer-Colorectal Cancer-And
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationt!k EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE
ACRUX (ACR) - ASX ANNOUNCEMENT 24 NOVEMBER 2014 EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE The European Medicines Agency (EMA) released a statement regarding the use of Testosterone Replacement Therapy
More informationAnalysis of Population Cancer Risk Factors in National Information System SVOD
Analysis of Population Cancer Risk Factors in National Information System SVOD Mužík J. 1, Dušek L. 1,2, Pavliš P. 1, Koptíková J. 1, Žaloudík J. 3, Vyzula R. 3 Abstract Human risk assessment requires
More informationRisk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes Dr. med. Henrik Csaba Horváth Why is risk stratification for colorectal cancer (CRC)
More informationtestosterone_pellet_implantation_for_androgen_deficiency_in_men 10/2015 N/A 11/2016 10/2015 This policy is not effective until December 30, 2015
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency_in_men
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationResearch Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources
Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources James Floyd, MD, MS Sep 17, 2015 UW Hospital Medicine Faculty Development Program Objectives Become more
More informationColorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed January 2013 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes it?
More informationTreatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)
Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical
More informationHormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.
Hormone Replacement Therapy : The New Debate Susan T. Hingle, M.D. Background Hormone replacement therapy (HRT) is extensively used in the United States, especially for: *treatment of menopausal symptoms
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationAtrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
More informationGASTROENTEROLOGY 2006;130:1872 1885
GASTROENTEROLOGY 2006;130:1872 1885 Guidelines for Colonoscopy Surveillance After Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationExamples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.
CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests
More informationPreventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64
Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral
More informationCommunicating uncertainty about benefits and
Communicating uncertainty about benefits and harms of pharmaceutical products Lisa M. Schwartz, MD, MS Steven Woloshin, MD, MS The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth
More informationImproving Colorectal Cancer Screening and Outcomes using an EMR Automation Model
Improving Colorectal Cancer Screening and Outcomes using an EMR Automation Model Background Knowledge Colorectal Cancer is the second leading cause of death from cancer in the United States. This year
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationSUPPLEMENTARY MATERIALS. Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial
1 SUPPLEMENTARY MATERIALS Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial Professor Ka Sing Lawrence Wong on behalf of The Executive Steering Committee and the ROCKET
More informationPrognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationGroup Critical Illness Insurance Provides lump-sum cash benefits that can help with daily expenses
What can living with a critical illness mean to you? Daily out-of-pocket expenses for fighting the disease while still paying your bills! GROCERIES CAR HOME PRESCRIPTIONS Benefit coverage for A Plus Benefits
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationButler Memorial Hospital Community Health Needs Assessment 2013
Butler Memorial Hospital Community Health Needs Assessment 2013 Butler County best represents the community that Butler Memorial Hospital serves. Butler Memorial Hospital (BMH) has conducted community
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationColorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed January 2016 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes it?
More informationThe WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
More informationCancer Screening and Early Detection Guidelines
Cancer Screening and Early Detection Guidelines Guillermo Tortolero Luna, MD, PhD Director Cancer Control and Population Sciences Program University of Puerto Rico Comprehensive Cancer Center ASPPR Clinical
More informationMeasures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationThe prognosis of gastrointestinal malignancies is strictly dependent on early detection of premalignant and malignant lesions
The prognosis of gastrointestinal malignancies is strictly dependent on early detection of premalignant and malignant lesions Early cancers in adenomatous lesions can be removed endoscopically (e.g. polypectomy,
More informationManagement of Symptomatic Atrial Fibrillation
Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015
More informationScreening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008
Dr. B. Levin is Professor Emeritus, The University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Lieberman is Chief, Division of Gastroenterology, Oregon Health and Science University, Portland
More informationcolon cancer Talk to your doctor about getting tested for colon cancer. They know how to prevent and you can, too. Take a look inside.
2006, American Cancer Society, Inc. No. 243900 Rev.01/08 The American Cancer Society is the nationwide community-based voluntary health organization dedicated to eliminating cancer as a major health problem
More information6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
More informationHow can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris
How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore
More informationBowel cancer: should I be screened?
Patient information from the BMJ Group Bowel cancer: should I be screened? Bowel cancer is a serious condition, but there are good treatments. Treatment works best if it's started early.to pick up early
More informationD. Risk Status: All patients who are at average risk, increased risk, or in need of surveillance are eligible for direct screening services.
ANTHC CRCCP Policy No. 001 Page 1 of 3 ANTHC CRCCP ELIGIBILITY Purpose: To establish and define the ANTHC CRCCP eligibility criteria for direct screening services. Eligibility will be determined by patient
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationGroup Critical Illness Insurance Provides lump-sum cash benefits that can help with daily expenses
What can living with a critical illness mean to you? Daily out-of-pocket expenses for fighting the disease while still paying your bills! GROCERIES CAR HOME PRESCRIPTIONS Benefit coverage for Catholic
More informationCancer Expert Working Group on Cancer Prevention and Screening. Prevention and Screening for Colorectal Cancer
Cancer Expert Working Group on Cancer Prevention and Screening Prevention and Screening for Colorectal Cancer 1 What is colorectal cancer? Colorectum (colon and rectum, or the large bowel or large intestine)
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationinflammation of the pancreas and damage to the an increased risk of hypertension, stroke and Table 7.1: Classification of alcohol consumption
H E A LT H SURVEY Alcohol Consumption 7 Alcohol Consumption N AT I O N A L Introduction Excessive alcohol consumption is associated with inflammation of the pancreas and damage to the an increased risk
More informationHealth risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study
DOI 10.1007/s00198-012-2224-2 ORIGINAL ARTICLE Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study R. L. Prentice & M. B. Pettinger
More information